Olema Pharmaceuticals Inc
OLMA8.350USD
+0.160+1.95%
收盘 11/07, 16:00（美东）报价延迟15分钟
573.04M总市值
亏损市盈率 TTM
关于 Olema Pharmaceuticals Inc 公司
Olema Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现、开发和商业化针对女性癌症的靶向疗法。其主要候选产品 OP-1250 是一种口服疗法，具有作为完全雌激素受体 (ER) 拮抗剂 (CERAN) 和选择性 ER 降解剂 (SERD) 的综合活性。该公司的 OP-1250 是一种口服小分子临床阶段候选产品，用于治疗内分泌驱动的癌症。OP-1250 作为单一疗法以及与细胞周期依赖性激酶 4 和 6 (CDK4/6) 抑制剂联合使用，在几种异种移植模型中表现出明显的肿瘤缩小效果，包括 ESR1 和 PIK3CA 突变和中枢神经系统 (CNS) 转移。目前该药物处于 I/II 期临床试验阶段，且处于 Ib/II 期临床试验阶段，与 palbociclib 联合用于治疗转移性 ER 阳性 (ER+)、人类表皮生长因子受体 2 阴性 (HER2-) 乳腺癌患者。
Olema Pharmaceuticals Inc简介
公司代码OLMA
公司名称Olema Pharmaceuticals Inc
上市日期Nov 19, 2020
CEOMr. Sean P. Bohen, M.D., Ph.D.
员工数量96
证券类型Ordinary Share
年结日Nov 19
公司地址780 Brannan Street
城市SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94103
电话14156513316
网址https://olema.com/
公司代码OLMA
上市日期Nov 19, 2020
CEOMr. Sean P. Bohen, M.D., Ph.D.
Olema Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ian Clark
Mr. Ian Clark
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sean P. Bohen, M.D., Ph.D.
Mr. Sean P. Bohen, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Shane Kovacs
Mr. Shane Kovacs
Chief Operating and Financial Officer
Chief Operating and Financial Officer
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 11月3日 周一
更新时间: 11月3日 周一
持股股东
股东类型
持股股东
持股股东
占比
Bain Capital Life Sciences Investors, LLC
9.97%
Paradigm BioCapital Advisors LP
9.86%
BVF Partners L.P.
7.72%
BlackRock Institutional Trust Company, N.A.
5.77%
Woodline Partners LP
5.11%
其他
61.58%
持股股东
持股股东
占比
Bain Capital Life Sciences Investors, LLC
9.97%
Paradigm BioCapital Advisors LP
9.86%
BVF Partners L.P.
7.72%
BlackRock Institutional Trust Company, N.A.
5.77%
Woodline Partners LP
5.11%
其他
61.58%
股东类型
持股股东
占比
Hedge Fund
33.44%
Investment Advisor
29.78%
Investment Advisor/Hedge Fund
27.87%
Venture Capital
9.80%
Research Firm
4.23%
Individual Investor
4.13%
Pension Fund
0.11%
Bank and Trust
0.11%
Insurance Company
0.03%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
315
72.32M
105.37%
-10.03M
2025Q2
320
70.59M
103.16%
-12.18M
2025Q1
327
72.74M
106.44%
-11.08M
2024Q4
313
78.82M
113.63%
+3.60M
2024Q3
301
63.64M
110.87%
-10.05M
2024Q2
299
62.60M
111.72%
-7.29M
2024Q1
288
60.06M
107.83%
-1.82M
2023Q4
271
55.06M
100.31%
-2.15M
2023Q3
263
50.27M
92.75%
-945.85K
2023Q2
259
39.52M
96.98%
-9.43M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Bain Capital Life Sciences Investors, LLC
6.84M
9.97%
--
--
Jun 30, 2025
Paradigm BioCapital Advisors LP
6.76M
9.86%
+23.00K
+0.34%
Jun 30, 2025
BVF Partners L.P.
5.30M
7.72%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.96M
5.77%
+637.23K
+19.20%
Jun 30, 2025
Woodline Partners LP
3.51M
5.11%
+2.03M
+137.22%
Jun 30, 2025
Deep Track Capital LP
3.44M
5.02%
--
--
Jun 30, 2025
Logos Global Management LP
3.21M
4.68%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.27M
4.76%
+395.39K
+13.77%
Jun 30, 2025
Janus Henderson Investors
3.02M
4.4%
+3.02M
--
Jun 30, 2025
Franklin Advisers, Inc.
3.01M
4.39%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.74%
ALPS Medical Breakthroughs ETF
0.39%
iShares Micro-Cap ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
iShares Health Innovation Active ETF
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.74%
ALPS Medical Breakthroughs ETF
占比0.39%
iShares Micro-Cap ETF
占比0.11%
Invesco Nasdaq Biotechnology ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
iShares Health Innovation Active ETF
占比0.06%
iShares Biotechnology ETF
占比0.05%
iShares Russell 2000 Value ETF
占比0.04%
Invesco RAFI US 1500 Small-Mid ETF
占比0.03%
Avantis US Small Cap Equity ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
